Bone morphogenic protein 3 inactivation is an early and frequent eventin colorectal cancer development (2008)
Loh, K,
Chia, J. A.,
Greco, S.,
Cozzi, S.J.,
Buttenshaw, R.L.,
Bond, C.E.,
...
Bone morphogenic proteins (BMPs) are members of the TGFB growth factor superfamily with well-described functions in bone formation. Although disrupted BMP signalling in tumor development has more...
VITATOPS, the VITAmins TO Prevent Stroke Trial: Rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444) (2007)
Hankey, Graeme J.,
Baker, R. I.,
Eikelboom, J. W.,
Gelavis, A.,
Hickling, S.,
Jamrozik, Konrad,
...
VITATOPS, the VITAmins TO Prevent Stroke Trial: Rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444) (2007)
Hankey, Graeme J.,
Baker, R. I.,
Eikelboom, J. W.,
Gelavis, A.,
Hickling, S.,
Jamrozik, Konrad,
...
Comparison study of cerebral protection using Ginkgo biloba extract and Losartan on stroked rats (2006)
Loh, K.,
Low, L.,
Wong, W.,
Zhou, S.,
Huang, S.,
Silva, R.,
...
It has been well documented that oxidative stress is involved in stroke. Currently, many neuroprotective strategies have been targeted at molecules that are able to act as an oxidant to intervene...
A comparison study of cerebral protection using Ginkgo biloba extract and Losartan on stroked rats (2006)
Loh, K.,
Low, L.,
Wong, W.,
Zhou, S.,
Huang, S.,
Silva, R.,
...
It has been well documented that oxidative stress is involved in stroke. Currently, many neuroprotective strategies have been targeted at molecules that are able to act as an oxidant to intervene...
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke - a randomized substud (2005)
Dusitanond, P,
Eikelboom, JW,
Hankey, GJ,
Thom, J,
Gilmore, G,
Loh, K,
...
Background and Purpose - Epidemiological and laboratory studies suggest that increasing concentrations of plasma homocysteine ( total homocysteine [tHcy]) accelerate cardiovascular disease by...
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not suppress blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with prior TIA or stroke: A randomized substudy of the Vitatops (vitamin (2005)
Hankey, GJ,
Eikelbloom, P,
Dusitanond, P,
Thom, J,
Loh, K,
Van Bockxmeer, F,
...
Homocysteine-lowering treatment with folic acid cobalamin and pyridoxine does not reduce blood markers of inflammation endothelial dysfunction or hypercoagulability in patients with previous transient ischemic attack or stroke : A Randomized Substudy of the VITATOPS Trial (2005)
Dusitanond, P.,
Eikelboom, J. W.,
Hankey, Graeme J.,
Thom, J.,
Gilmore, G.,
Loh, K.,
...
© 2005 American Heart Association
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: A randomized substudy of the VITATOPS trial (2005)
Dusitanond, P.,
Eikelboom, J.W.,
Hankey, G.J.,
Thom, J.,
Gilmore, G.,
Loh, K.,
...
© 2005 American Heart Association, Inc.
Homocysteine-lowering treatment with folic acid cobalamin and pyridoxine does not reduce blood markers of inflammation endothelial dysfunction or hypercoagulability in patients with previous transient ischemic attack or stroke : A Randomized Substudy of the VITATOPS Trial (2005)
Dusitanond, P.,
Eikelboom, J. W.,
Hankey, Graeme J.,
Thom, J.,
Gilmore, G.,
Loh, K.,
...
© 2005 American Heart Association
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: A randomized substudy of the VITATOPS trial (2005)
Dusitanond, P.,
Eikelboom, J.W.,
Hankey, G.J.,
Thom, J.,
Gilmore, G.,
Loh, K.,
...
© 2005 American Heart Association, Inc.
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke - a randomized substud (2005)
Dusitanond, P,
Eikelboom, JW,
Hankey, GJ,
Thom, J,
Gilmore, G,
Loh, K,
...
Background and Purpose - Epidemiological and laboratory studies suggest that increasing concentrations of plasma homocysteine ( total homocysteine [tHcy]) accelerate cardiovascular disease by...
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not suppress blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with prior TIA or stroke: A randomized substudy of the Vitatops (vitamin (2005)
Hankey, GJ,
Eikelbloom, P,
Dusitanond, P,
Thom, J,
Loh, K,
Van Bockxmeer, F,
...
Quantitation of renal function based on two-compartmental modeling of renal pelvis (2005)
Loh, K,
Ng, D,
Ghista, D,
Rudolph, H
The primary functions of the kidney are: (i) to get rid of the body waste materials that are either ingested or produced by metabolism, and (ii) to control the volume and composition of the body...
Is there really a power shortage in clinical trials testing the "Homocysteine hypothesis"? Preliminary results from the VITAmins TO prevent stroke (VITATOPS) trial (2004)
Hankey, GJ,
Elkelboom, JW,
Loh, K,
Yi, QL,
Tang, M,
Pizzi, J,
...
Is there really a power shortage in clinical trials testing the "homocysteine hypothesis?" Results from a substudy of the VITAmins TO Prevent Stroke (VITATOPS) Trial (2004)
Hankey, GJ,
Eikelboom, JW,
Loh, K,
Yi, Q,
Pizzi, J,
Tang, M,
...
Is there really a power shortage in clinical trials testing the "homocysteine hypothesis?". (2004)
Hankey, G.J.,
Eikelboom, J.W.,
Loh, K.,
Yi, Q.,
Pizzi, J.,
Tang, M.,
...
© 2004 American Heart Association, Inc.
Is there really a power shortage in clinical trials testing the "homocysteine hypothesis?". (2004)
Hankey, G.J.,
Eikelboom, J.W.,
Loh, K.,
Yi, Q.,
Pizzi, J.,
Tang, M.,
...
© 2004 American Heart Association, Inc.
Is there really a power shortage in clinical trials testing the "Homocysteine hypothesis"? Preliminary results from the VITAmins TO prevent stroke (VITATOPS) trial (2004)
Hankey, GJ,
Elkelboom, JW,
Loh, K,
Yi, QL,
Tang, M,
Pizzi, J,
...
Is there really a power shortage in clinical trials testing the "homocysteine hypothesis?" Results from a substudy of the VITAmins TO Prevent Stroke (VITATOPS) Trial (2004)
Hankey, G J,
Eikelboom, J W,
Loh, K,
Yi, Q,
Pizzi, J,
Tang, M,
...
Is there really a power shortage in clinical trials testing the "Homocysteine hypothesis"? Preliminary results from the VITAmins TO prevent stroke (VITATOPS) trial
Hankey, GJ,
Elkelboom, JW,
Loh, K,
Yi, QL,
Tang, M,
Pizzi, J,
...
Is there really a power shortage in clinical trials testing the "homocysteine hypothesis?" Results from a substudy of the VITAmins TO Prevent Stroke (VITATOPS) Trial
Hankey, GJ,
Eikelboom, JW,
Loh, K,
Yi, Q,
Pizzi, J,
Tang, M,
...
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke - a randomized substudy
Dusitanond, P,
Eikelboom, JW,
Hankey, GJ,
Thom, J,
Gilmore, G,
Loh, K,
...
Background and Purpose - Epidemiological and laboratory studies suggest that increasing concentrations of plasma homocysteine ( total homocysteine [tHcy]) accelerate cardiovascular disease by...
Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not suppress blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with prior TIA or stroke: A randomized substudy of the Vitatops (vitami
Hankey, GJ,
Eikelbloom, P,
Dusitanond, P,
Thom, J,
Loh, K,
Van Bockxmeer, F,
...
Amiodarone-induced thyroid disorders: a clinical review
Loh, K.
Although amiodarone is regarded as a highly effective anti-arrhythmic agent, its use may lead to alterations in thyroid gland function and/or thyroid hormone metabolism, partly because of its rich...